PhenoTarget Biosciences, Inc. is a biotech startup developing first-in-class therapeutics for fibrotic diseases and aging-related conditions. We have three small molecule programs: (1) YAP inhibitor that blocks myofibroblast activation as first-in-class antifibrotic therapeutics for fibrosis in the lung, heart, liver, muscle and kidneys; (2) senolytic compounds selectively kill senescent cells as an anti-aging therapy for chronic diseases including MASH and CKD; and (3) a brain-penetrating compound that reverses cellular senescence for aging-related neurodegenerative diseases including Alzheimer's and Parkinson's. Our lead program is at advanced stage of lead optimization that we will select a development candidate by the end of 2024 and file for IND Q2 2026.
The fund raised here will be used to support the selection of the development candidate for the antifibrotic program. We have engaged in conversations with pharma for potential partnership and got feedback from multiple parties that a data package with the selected development candidate will likely trigger a collaboration/partnership. This will also position us well to raise seed round finance ($10M) to move the programs into clinic.
The fund will also be used to kick off medicinal chemistry efforts for the two anti-aging programs to identify compounds with improved potency and pharmacological properties.
Ready to Ask For Funding for your company?
Post a Funding Request